Antiviral treatment and statin use and risk of decompensated cirrhosis in patients with hepatitis C: a time-dependent analysis of a retrospective cohort study - Takeaways - MDSpire

Antiviral treatment and statin use and risk of decompensated cirrhosis in patients with hepatitis C: a time-dependent analysis of a retrospective cohort study

  • By

  • Kimberly A Brown

  • Stuart C Gordon

  • Yichu Wang

  • Trueman Wu

  • Sheri Trudeau

  • Loralee B Rupp

  • Yihe G Daida

  • Mark A Schmidt

  • Mei Lu

  • March 27, 2026

Share

  • 1

    Sustained virological response (SVR) in hepatitis C patients is linked to slower cirrhosis progression.

  • 2

    Statin treatment is associated with a reduced risk of decompensated cirrhosis (DC) in patients with hepatitis C.

  • 3

    The study analyzed data from 16,275 hepatitis C patients, observing 1,718 incidents of DC and 2,398 deaths.

  • 4

    By year 15, antiviral treatment rates increased from 36% to 11%, while statin use rose from 12% to 28%.

  • 5

    Both SVR and statin use independently lower the risk of decompensation in hepatitis C patients.

Original Source(s)

Antiviral treatment and statin use and risk of decompensated cirrhosis in patients with hepatitis C: a time-dependent analysis of a retrospective cohort study

  • by Kimberly A Brown, Stuart C Gordon, Yichu Wang, Trueman Wu, Sheri Trudeau, Loralee B Rupp, Yihe G Daida, Mark A Schmidt, Mei Lu

  • March 27, 2026

Related Content

The FUEL FALD Study: Effects of Udenafil on Liver Stiffness and Fibrosis after Fontan

Trained immunity as a systemic bridge: the liver-gut-immune-oral axis in the comorbidity of chronic liver disease and periodontitis

Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications